Literature DB >> 23440763

Viral infection transiently reverses activation receptor-mediated NK cell hyporesponsiveness in an MHC class I-independent mechanism.

Budhaditya Mazumdar1, Fred D Bolanos, Sandeep K Tripathy.   

Abstract

Continuous engagement of the Ly49H activating receptor with its ligand (m157) in a transgenic mouse expressing m157 (m157-Tg) results in hyporesponsiveness of Ly49H(+) NK cells. The same interaction, during murine cytomegalovirus (MCMV) infection, leads to activation of Ly49H(+) NK cells. MCMV infection results in decreased MHC class I (MHC-I) expression on the infected cell as well as inflammatory responses, both of which do not take place in the uninfected m157-Tg mouse, potentially allowing for activation of NK cells in the context of MCMV infection. In this study, we demonstrated that viral infection transiently reverses activation receptor-mediated NK cell hyporesponsiveness in an MHC-I-independent mechanism. Furthermore, Ly49H(+) NK cells in an MHC-I-deficient environment remained hyporesponsive in the context of m157 expression, even when mature WT splenocytes were transferred into m157-Tg mice in an MHC-I-deficient environment. However, the administration of cytokines TNF-α, IL-12, and IFN-β resulted in a partial recovery from activation receptor-induced hyporesponsiveness. Thus, the release of the aforementioned cytokines during MCMV infection and not the downregulation of MHC-I expression appears to be responsible for partial resolution of Ly49H receptor-induced NK cell hyporesponsiveness.
© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23440763      PMCID: PMC3740970          DOI: 10.1002/eji.201243215

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  41 in total

1.  Vital involvement of a natural killer cell activation receptor in resistance to viral infection.

Authors:  M G Brown; A O Dokun; J W Heusel; H R Smith; D L Beckman; E A Blattenberger; C E Dubbelde; L R Stone; A A Scalzo; W M Yokoyama
Journal:  Science       Date:  2001-05-04       Impact factor: 47.728

2.  Tuning of natural killer cell reactivity by NKp46 and Helios calibrates T cell responses.

Authors:  Emilie Narni-Mancinelli; Baptiste N Jaeger; Claire Bernat; Aurore Fenis; Sam Kung; Aude De Gassart; Sajid Mahmood; Marta Gut; Simon C Heath; Jordi Estellé; Elodie Bertosio; Frédéric Vely; Louis N Gastinel; Bruce Beutler; Bernard Malissen; Marie Malissen; Ivo G Gut; Eric Vivier; Sophie Ugolini
Journal:  Science       Date:  2012-01-20       Impact factor: 47.728

3.  Specific and nonspecific NK cell activation during virus infection.

Authors:  A O Dokun; S Kim; H R Smith; H S Kang; D T Chu; W M Yokoyama
Journal:  Nat Immunol       Date:  2001-10       Impact factor: 25.606

4.  Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection.

Authors:  Khuong B Nguyen; Thais P Salazar-Mather; Marc Y Dalod; Jeffrey B Van Deusen; Xiao-qing Wei; Foo Y Liew; Michael A Caligiuri; Joan E Durbin; Christine A Biron
Journal:  J Immunol       Date:  2002-10-15       Impact factor: 5.422

5.  Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors.

Authors:  Hisashi Arase; Edward S Mocarski; Ann E Campbell; Ann B Hill; Lewis L Lanier
Journal:  Science       Date:  2002-04-11       Impact factor: 47.728

6.  MCMV glycoprotein gp40 confers virus resistance to CD8+ T cells and NK cells in vivo.

Authors:  Astrid Krmpotić; Dirk H Busch; Ivan Bubić; Friedemann Gebhardt; Hartmut Hengel; Milena Hasan; Anthony A Scalzo; Ulrich H Koszinowski; Stipan Jonjić
Journal:  Nat Immunol       Date:  2002-05-20       Impact factor: 25.606

7.  The murine cytomegalovirus immunomodulatory gene m152 prevents recognition of infected cells by M45-specific CTL but does not alter the immunodominance of the M45-specific CD8 T cell response in vivo.

Authors:  Marielle C Gold; Michael W Munks; Markus Wagner; Ulrich H Koszinowski; Ann B Hill; Steven P Fling
Journal:  J Immunol       Date:  2002-07-01       Impact factor: 5.422

Review 8.  Interleukin-12 and the regulation of innate resistance and adaptive immunity.

Authors:  Giorgio Trinchieri
Journal:  Nat Rev Immunol       Date:  2003-02       Impact factor: 53.106

9.  Recognition of a virus-encoded ligand by a natural killer cell activation receptor.

Authors:  Hamish R C Smith; Jonathan W Heusel; Indira K Mehta; Sungjin Kim; Brigitte G Dorner; Olga V Naidenko; Koho Iizuka; Hiroshi Furukawa; Diana L Beckman; Jeanette T Pingel; Anthony A Scalzo; Daved H Fremont; Wayne M Yokoyama
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-11       Impact factor: 11.205

10.  Self-association of an activating natural killer cell receptor, KIR2DS1.

Authors:  Michael Hayley; Sarah Bourbigot; Valerie Booth
Journal:  PLoS One       Date:  2011-08-30       Impact factor: 3.240

View more
  5 in total

1.  Acquisition of activation receptor ligand by trogocytosis renders NK cells hyporesponsive.

Authors:  Cathrine A Miner; Tusar K Giri; Claire E Meyer; Mark Shabsovich; Sandeep K Tripathy
Journal:  J Immunol       Date:  2015-01-12       Impact factor: 5.422

2.  Ionomycin Treatment Renders NK Cells Hyporesponsive.

Authors:  Gema Romera-Cárdenas; L Michael Thomas; Sheila Lopez-Cobo; Eva M García-Cuesta; Eric O Long; Hugh T Reyburn
Journal:  PLoS One       Date:  2016-03-23       Impact factor: 3.240

3.  Expression of the inhibitory receptor NKG2A correlates with increased liver and splenic NK cell response to activating receptor engagement.

Authors:  Claire E Meyer; Phillip N Key; Toby Zhu; Mark Shabsovich; Ann Ni; Sandeep K Tripathy
Journal:  Immun Inflamm Dis       Date:  2017-03-24

Review 4.  NK cell education via nonclassical MHC and non-MHC ligands.

Authors:  Yuke He; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2016-06-06       Impact factor: 11.530

Review 5.  NK Cell Hyporesponsiveness: More Is Not Always Better.

Authors:  Marie Frutoso; Erwan Mortier
Journal:  Int J Mol Sci       Date:  2019-09-12       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.